Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trialsLICHTENSTEIN, G. R; ZAKKO, S; GORDON, G. L et al.Alimentary pharmacology & therapeutics. 2012, Vol 36, Num 2, pp 126-134, issn 0269-2813, 9 p.Article

Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazolBRAMER, S. L; FORBES, W. P.Clinical pharmacokinetics. 1999, Vol 37, pp 25-32, issn 0312-5963, SUP2Article

Interaction potential and tolerability of the coadministration of cilostazol and aspirinMALLIKAARJUN, S; FORBES, W. P; BRAMER, S. L et al.Clinical pharmacokinetics. 1999, Vol 37, pp 87-93, issn 0312-5963, SUP2Article

Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial diseaseBRAMER, S. L; FORBES, W. P; MALLIKAARJUN, S et al.Clinical pharmacokinetics. 1999, Vol 37, pp 1-11, issn 0312-5963, SUP2Article

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trialsSCHOENFELD, P; PIMENTEL, M; CHANG, L et al.Alimentary pharmacology & therapeutics. 2014, Vol 39, Num 10, pp 1161-1168, issn 0269-2813, 8 p.Article

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: a double-blind placebo-controlled studySANYAL, A; YOUNOSSI, Z. M; BORTEY, E et al.Alimentary pharmacology & therapeutics. 2011, Vol 34, Num 8, pp 853-861, issn 0269-2813, 9 p.Article

Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trialLICHTENSTEIN, G. R; GORDON, G. L; ZAKKO, S et al.Alimentary pharmacology & therapeutics. 2010, Vol 32, Num 8, pp 990-999, issn 0269-2813, 10 p.Article

A new pharmacological treatment for intermittent claudication : Results of a randomized, multicenter trialBEEBE, H. G; DAWSON, D. L; CUTLER, B. S et al.Archives of internal medicine (1960). 1999, Vol 159, Num 17, pp 2041-2050, issn 0003-9926Article

Pharmacokinetics of multiple-dose oral cilostazol in middle-age and elderly men and womenSURI, A; FORBES, W. P; BRAMER, S. L et al.Journal of clinical pharmacology. 1998, Vol 38, Num 2, pp 144-150, issn 0091-2700Article

Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudicationELAM, M. B; HECKMAN, J; CROUSE, J. R et al.Arteriosclerosis, thrombosis, and vascular biology. 1998, Vol 18, Num 12, pp 1942-1947, issn 1079-5642Article

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. DiscussionMONEY, S. R; HERD, J. A; MOORE, W. S et al.Journal of vascular surgery. 1998, Vol 27, Num 2, pp 267-275, issn 0741-5214Conference Paper

Role of milrinone in the management of congestive heart failureHILLEMAN, D. E; FORBES, W. P.DICP (Cincinnati, Ohio). 1989, Vol 23, Num 5, pp 357-362, issn 1042-9611Article